ATE382345T1 - Fluvastatin-arzneimittel mit verzögerter wirkstoffabgabe - Google Patents

Fluvastatin-arzneimittel mit verzögerter wirkstoffabgabe

Info

Publication number
ATE382345T1
ATE382345T1 AT99947489T AT99947489T ATE382345T1 AT E382345 T1 ATE382345 T1 AT E382345T1 AT 99947489 T AT99947489 T AT 99947489T AT 99947489 T AT99947489 T AT 99947489T AT E382345 T1 ATE382345 T1 AT E382345T1
Authority
AT
Austria
Prior art keywords
fluvastatin
delayed
release medicine
medicine
release
Prior art date
Application number
AT99947489T
Other languages
English (en)
Inventor
Rajen Shah
Arun Patel
Roy Sandry
Original Assignee
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22627919&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE382345(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh
Application granted granted Critical
Publication of ATE382345T1 publication Critical patent/ATE382345T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT99947489T 1998-10-14 1999-10-12 Fluvastatin-arzneimittel mit verzögerter wirkstoffabgabe ATE382345T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17249198A 1998-10-14 1998-10-14

Publications (1)

Publication Number Publication Date
ATE382345T1 true ATE382345T1 (de) 2008-01-15

Family

ID=22627919

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99947489T ATE382345T1 (de) 1998-10-14 1999-10-12 Fluvastatin-arzneimittel mit verzögerter wirkstoffabgabe

Country Status (30)

Country Link
EP (1) EP1121116B1 (de)
JP (2) JP2002527388A (de)
KR (1) KR100517090B1 (de)
CN (1) CN1196481C (de)
AR (2) AR020780A1 (de)
AT (1) ATE382345T1 (de)
AU (1) AU765475B2 (de)
BR (1) BR9911648A (de)
CA (1) CA2346868C (de)
CO (1) CO5140079A1 (de)
CY (1) CY1107874T1 (de)
DE (1) DE69937891T2 (de)
DK (1) DK1121116T3 (de)
ES (1) ES2297936T3 (de)
HK (1) HK1040920B (de)
HU (1) HUP0104268A3 (de)
ID (1) ID29350A (de)
IL (2) IL142375A0 (de)
MY (1) MY121105A (de)
NO (1) NO327285B1 (de)
NZ (1) NZ511010A (de)
PE (1) PE20001110A1 (de)
PL (1) PL198850B1 (de)
PT (1) PT1121116E (de)
RU (1) RU2259826C2 (de)
SK (2) SK286595B6 (de)
TR (1) TR200101088T2 (de)
TW (1) TW577738B (de)
WO (1) WO2000021525A2 (de)
ZA (1) ZA200103001B (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6569461B1 (en) 1999-03-08 2003-05-27 Merck & Co., Inc. Dihydroxy open-acid and salts of HMG-CoA reductase inhibitors
US6242003B1 (en) * 2000-04-13 2001-06-05 Novartis Ag Organic compounds
WO2001093859A1 (en) 2000-06-09 2001-12-13 Lek Pharmaceuticals D.D. Stable pharmaceutical product and formulation
DZ3473A1 (fr) * 2000-09-29 2002-04-04 Solvay Pharm Bv Formulation pharmaceutique a liberation prolongee independante de la force ionique.
US20060127474A1 (en) 2001-04-11 2006-06-15 Oskar Kalb Pharmaceutical compositions comprising fluvastatin
WO2004024184A1 (ja) * 2002-09-11 2004-03-25 Takeda Pharmaceutical Company Limited 徐放性製剤
US20070042143A1 (en) 2003-04-23 2007-02-22 Ferring B.V. Sachet for a pharmaceutical composition
US8987322B2 (en) * 2003-11-04 2015-03-24 Circ Pharma Research And Development Limited Pharmaceutical formulations for carrier-mediated transport statins and uses thereof
DE102004062475A1 (de) * 2004-12-24 2006-07-06 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung
KR100582347B1 (ko) * 2004-12-30 2006-05-22 한미약품 주식회사 3-하이드록시-3-메틸글루타릴 조효소 a 환원효소 억제제및 고혈압 치료제의 복합제제 및 그의 제조방법
WO2007016757A1 (en) * 2005-08-05 2007-02-15 Orbus Pharma Inc. Stabilized extended release pharmeceutical compositions comprising an hmg-coa reductase inhibitor
MX2008010879A (es) * 2006-02-24 2008-10-27 Teva Pharma Composiciones farmaceuticas de sodio de fluvastatina.
RU2356532C2 (ru) * 2007-06-01 2009-05-27 Открытое Акционерное Общество "Отечественные Лекарства" Фармацевтическая композиция проксодолола с контролируемым высвобождением
CN102805739B (zh) * 2012-04-10 2013-08-14 宋芸 氟伐他汀钠缓释包衣滴丸及其制备方法
SG11201505352RA (en) * 2013-01-09 2015-08-28 Edgemont Pharmaceuticals Llc Controlled release formulations of lorazepam
CN106344535B (zh) * 2016-08-29 2019-09-20 济南康和医药科技有限公司 一种氟伐他汀钠微孔渗透泵控释片及其制备方法
EP3720434A4 (de) 2017-12-05 2021-09-01 Sunovion Pharmaceuticals Inc. Nicht-racemische gemische und deren verwendung
US10377708B2 (en) 2017-12-05 2019-08-13 Sunovion Pharmaceuticals Inc. Crystal forms and production methods thereof
US11802103B2 (en) 2018-09-25 2023-10-31 Ponce De Leon Health Designated Activity Company Process of making calcium alpha-ketoglutarate
AU2020286441A1 (en) 2019-06-04 2022-01-06 Sunovion Pharmaceuticals Inc. Modified release formulations and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4915954A (en) * 1987-09-03 1990-04-10 Alza Corporation Dosage form for delivering a drug at two different rates
CA2045428A1 (en) * 1990-06-26 1991-12-27 Alfred W. Alberts Method for enhancing the lowering of plasma cholesterol levels
GB9523752D0 (en) * 1995-11-21 1996-01-24 Pfizer Ltd Pharmaceutical formulations
UA29513C2 (uk) * 1995-12-22 2000-11-15 Кова Компані, Лтд Фармацевтична композиція, що включає (е)-3,5-дигідрокси-7-[4'-4''-фторфеніл-2'-циклопропілхінолін-3'-іл]-6- гептенову кислоту
SE9603667D0 (sv) * 1996-10-08 1996-10-08 Astra Ab Pharmaceutical compositions

Also Published As

Publication number Publication date
ID29350A (id) 2001-08-23
CA2346868C (en) 2008-09-09
SK286596B6 (sk) 2009-01-07
JP2002527388A (ja) 2002-08-27
MY121105A (en) 2005-12-30
IL142375A (en) 2012-01-31
AU6090999A (en) 2000-05-01
IL142375A0 (en) 2002-03-10
PE20001110A1 (es) 2000-11-01
KR20010080156A (ko) 2001-08-22
HK1040920B (zh) 2005-07-29
CY1107874T1 (el) 2013-06-19
HUP0104268A2 (hu) 2002-04-29
SK286595B6 (sk) 2009-01-07
NO20011695D0 (no) 2001-04-04
RU2259826C2 (ru) 2005-09-10
NZ511010A (en) 2003-10-31
AR069281A2 (es) 2010-01-13
ZA200103001B (en) 2002-07-11
CO5140079A1 (es) 2002-03-22
AR020780A1 (es) 2002-05-29
HUP0104268A3 (en) 2002-06-28
EP1121116B1 (de) 2008-01-02
DE69937891T2 (de) 2008-12-11
CN1328454A (zh) 2001-12-26
AU765475B2 (en) 2003-09-18
WO2000021525A2 (en) 2000-04-20
SK5092001A3 (en) 2001-09-11
PL198850B1 (pl) 2008-07-31
PL348109A1 (en) 2002-05-06
PT1121116E (pt) 2008-03-12
EP1121116A2 (de) 2001-08-08
KR100517090B1 (ko) 2005-09-27
WO2000021525A3 (en) 2000-08-10
BR9911648A (pt) 2001-03-20
HK1040920A1 (en) 2002-06-28
NO20011695L (no) 2001-05-30
TW577738B (en) 2004-03-01
ES2297936T3 (es) 2008-05-01
JP4938383B2 (ja) 2012-05-23
JP2006298945A (ja) 2006-11-02
CN1196481C (zh) 2005-04-13
DE69937891D1 (de) 2008-02-14
CA2346868A1 (en) 2000-04-20
NO327285B1 (no) 2009-06-02
TR200101088T2 (tr) 2001-10-22
DK1121116T3 (da) 2008-05-13

Similar Documents

Publication Publication Date Title
ATE382345T1 (de) Fluvastatin-arzneimittel mit verzögerter wirkstoffabgabe
DE59814019D1 (de) 2-benzoyl-cyclohexan-1,3-dione
TR199801781A3 (tr) Sapkali tarak.
NL1010255A1 (nl) Bollenplanter.
ES1040856Y (es) Envase.
ATE231848T1 (de) Substituierte 2-benzoyl-cyclohexan-1,3-dione
FI972885A0 (fi) Anordning foer utfoering av en divisionoperation, saerskilt i en tredimensionell grafik
ES1041026Y (es) Vibrador terapeutico.
ES1041208Y (es) Contenedor ligero perfeccionado.
ES1042496Y (es) "pilona sumible".
ES1037395Y (es) Tendedero antilluvia.
ES1043470Y (es) Lampara terapeutica.
ITCA970019A0 (it) Beccuccio.
ES1043918Y (es) Linterna perfeccionada.
ES1037895Y (es) Lampara perfeccionada.
ITBO990070U4 (it) Vassoio - contenitore per alimenti .
ES1036158Y (es) Biberon perfeccionado.
IT1291226B1 (it) Girello per bambini.
ITPR970022V0 (it) Profilorete asimmetrico.
UA25523A (uk) Лікувальhий препарат гірчичhик
ES1037945Y (es) Envase.
FI971391A0 (fi) Koppling laemplig foer spaenningsarbete, saerskilt koppling foer ljusbaogs- eller oeverstoemsskydd
FI971438A0 (fi) Koppling laemplig foer spaennings- eller spaenningsfri arbete, saerskilt koppling foer ljusbaogs- eller oeverstoemsskydd
ID19473A (id) 24-homo-26,27-heksafluoro-kolkalsiferol
ES1036836Y (es) Envase perfeccionado.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1121116

Country of ref document: EP